Portfolio

We are enabling companies to turn their boldest ambitions into world-changing breakthroughs in healthcare and technology.

Portfolio

Spotlights Portfolio List

Portfolio List

Explores Glia's role in brain disease, acquired by Neumora.
Acquired by Neumora
Develops innovative embolotherapy using inorganic polymer microspheres for hypervascular tumors.
Develops nausea treatments for surgical and cancer patients.
Acquired by Eagle Pharmaceuticals / EURONEXT: ACPH
Democratizes flow cytometry for medical research.
Acquired by Becton Dickinson
Develops innovative therapies for unmet needs in dermatology and immunodermatology.
NASDAQ:ACRS
Uses Smart Antibody Technology to accelerate development and reduce costs in antibody discovery.
NASDAQ: ADAG
Develops engineered T-cell therapies (TCR T-cells) to treat solid tumor and hematological cancers.
NASDAQ: ADAP
Develops protein conjugate therapies, combining biologics and small molecule payloads to treat cancer.
Uses genome-wide methylation analysis for earlier, precise cancer and morbidity detection.
Developing a protein nanoparticle (PNP) delivery platform.
Develops transformative gene therapies for devastating diseases using rationally designed AAV vectors.
Develops targeted radioligand therapies (RLTs) to improve cancer treatment globally.
Develops precision medicines targeting protein synthesis for breakthrough cancer therapies.
Developing Amber-UI neuromodulation therapy using Picostim for urinary incontinence.
Developed minimally invasive medical devices to restore quality of life from Overactive Bladder Syndrome.
Acquired by Hologic
Develops novel therapies by inhibiting the complement system at the C3 level.
NASDAQ: APLS
Develops alpha radioligand therapies (ARTs) for targeted cancer treatment with resilient supply chain.
Developed Ontozry™ (cenobamate) to treat epilepsy.
Acquired by Angelini Pharma
Developing neurodegenerative disease treatments using proprietary RNA interference platform.
Develops improved therapies for idiopathic pulmonary fibrosis (IPF) and other respiratory diseases.
Develops CAR-T cell therapies using switchable and scalable platforms for cancers.
Pioneering gene therapy company focused on transformative medicines for neurodegenerative disorders.
Developing innovative neuromodulation technology to treat large disease populations.
Developing innovative neuromodulation technology to treat large disease populations.
Develops innovative orthopedic solutions to restore patient mobility and enhance surgical outcomes.
Pioneering CRISPR base editing for precision genetic medicines to treat disease.
NASDAQ: BEAM
Develops and commercializes novel digital programmable hearing aid solutions for China.
Develops biologics combining targeted therapy with tumor modulators to enhance immune activity.
NASDAQ:BCAX
Focuses on developing therapies for diseases of the eye.
Acquired by Shire
Developed a CE-Marked product for improving dialysis access surgery.
Developing base editing technology for a range of applications.
Develops and commercializes high-quality hyaluronic acid (HA) based products for the Chinese market.
Precision therapy company striving to improve human health.
Acquired by Sanofi / NASDAQ: BPMC
Develops fully autonomous farming robots to automate tasks and enhance workforce efficiency.
Develops therapies for epilepsy and other neurological disorders with neural implant technology.
Provides affordable, convenient, and effective orthodontic solutions through clear aligners and remote monitoring.
Rapidly growing pharmaceutical company focusing on emerging markets and expanding into regulated markets.
Developed lixivaptan for hyponatremia treatment.
Acquired by Cornerstone Therapeutics
Pioneering CRISPR genome editing for new medical therapies.
NASDAQ: CRBU
Transforming warehouse operations through robotic automation.
Employs DragonFold technology for rapid protein/ligand co-folding to develop novel drugs.
Immune-activating cancer therapy company acquired by Regeneron in 2022, developed vidutolimod.
Acquired by Regeneron / NASDAQ: CMPI
Develops and commercializes consumer healthcare and over-the-counter products.
Develops antibody-coupled T-cell receptor platform to target and kill tumor cells.
NASDAQ:COGT
Develops and commercializes high-quality biosimilar therapeutics worldwide using advanced analytics.
Developing the first therapy targeting a root cause of preterm preeclampsia to reduce risks for mothers and babies, including premature birth.
Develops antibodies targeting tumor-immune synapse for comprehensive cancer treatment.
NASDAQ: CMPX
Provides high-end diagnostics for disease stratification and therapy selection.
Acquired by Metropolis Healthcare
Redefining PCR with single-molecule precision and category-defining sensitivity.
Leader in discovery and development of novel drugs in stem cell related diseases.
Seed-stage venture firm and accelerator for therapeutics startups, providing expertise and capital.
Provides compact, affordable flow cytometry instruments with high multiplexing capabilities.
NASDAQ: CTBK
Developing therapies for neurodegenerative diseases through rigorous research.
NASDAQ: DNLI
AAV gene therapy developer for rare diseases.
Acquired by Ultragenyx Pharmaceuticals
Developing curative medicines through precision in vivo cellular engineering.
Specializing in biosimilars and novel biologics for global healthcare markets.
Developing innovative treatments for eye diseases and vision disorders.
SHA: 688050
Focused on affordable, high-quality medicines for patients worldwide.
Developing pulsed field ablation technology for cardiac arrhythmia treatment.
Acquired by Boston Scientific
Developing small molecule therapeutics for protein misfolding and aggregation diseases.
Acquired by Pfizer
Improving diagnostic testing and accelerate drug discovery in diverse underserved populations.
Leading animal vaccine manufacturer in China.
603718.SS
Hemostatic product manufacturer in China.
Developing innovative drugs for diabetes and related metabolic disorders.
2552.KHK
Developing Midazolam Nasal Spray (USL261) for acute repetitive seizures.
Acquired by UCB
Leading the change in cell & gene therapies & personalized immunotherapy.
Dedicated to developing novel treatments for fibrotic diseases.
Developing and commercializing high-quality biologic medicines.
1801.HK
Harnessing deep learning to accelerate pharmaceutical development.
Developing therapies for serious and rare diseases, including respiratory and inflammatory conditions.
NASDAQ: INSM
Developing novel protein-based therapeutics for companion animals.
Acquired by Dechra
Developing and commercializing innovative medicines focused on gastrointestinal diseases.
NASDAQ: IRWD
Eliminating infusion-related patient harm.
Acquired by Fresenius Kabi
Developing novel treatments for unmet medical needs.
Targets epigenetic pathways to develop innovative cancer therapies.
Developing innovative therapies for autoimmune and inflammatory diseases.
NASDAQ: LSB
Engineering microbes to produce animal-free proteins and growth factors for biopharma, food, health, and personal care markets.
Research-driven pharmaceutical manufacturing organization.
NSE: LAURUSLABS
Develops and produces insulin pumps.
Developing nasal spray products to prevent respiratory viruses.
Developing innovative vaccines for the prevention of gastrointestinal diseases.
Acquired by Takeda
Manufactures, develops, and commercializes high quality, affordably priced cardiovascular and general surgery medical devices.
Developing antibody-drug conjugates for cancer treatment.
NASDAQ: MRSN
Bringing cell-based therapies to heart failure patients.
Developing next-generation medicines for obesity and metabolic diseases.
NASDAQ: MTSR
Develops targeted therapies for rare genetic diseases and mitochondrial disorders.
Acquired by Zogenix
Manufactures and markets minimally invasive interventional therapy medical devices in the field of ENT, cardiovascular and others.
Developing precision medicines for brain diseases.
NASDAQ: NMRA
Creates and promotes differentiated products in the pediatric market.
Acquired by Pfizer
Develops targeted therapies for fibrotic diseases and other dermatological conditions.
Developing novel therapeutics for neurogenic cough and inflammation.
Developing small molecule inhibitors of the NLRP3 inflammasome.
Develops innovative therapies to address unmet medical needs in various diseases.
Acquired by SciClone
Accelerating the advancement of globally competitive oncology assets for patients.
Developing sustainable, electric self-driving systems for urban mobility.
Acquired by Magna
Developing treatments for rare diseases using bone-marrow gene therapy.
NASDAQ: ORTX
Promotes the development of cervical cancer screening and prevention in China.
Offers clean-label wellness supplements for health-conscious consumers through plant-based nutrition.
Developing and introducing effective and clinically proven children's medicines for China.
Designing novel therapeutics against previously undruggable targets using experimental and computational biophysics.
Developing and supplying plasma protein therapies for the treatment of rare and chronic diseases.
Revolutionizing the future of transportation by building the safest and most reliable self-driving technology.
NASDAQ: PONY
Engineering advanced therapies for genetic and oncological diseases through genome editing.
NASDAQ: DTIL
Pioneering gene-editing solutions using precision genome engineering technologies.
NASDAQ: PRME
Developing therapies for neuropsychiatric and neurodevelopmental disorders.
Developing therapies targeting protein misfolding diseases.
Merged with Yumanity Therapeutics in 2020
Developing inhaled therapies for severe respiratory infections and lung conditions.
Empowering financial institutions with insights for wealth management solutions through data aggregation.
NASDAQ: RLYB
Developing precision diagnostic solutions for cell analysis and research.
Developing and commercializing therapies for rare diseases in Asia.
Providing quality medical equipment and supporting healthcare professionals and patients.
Advancing AAV-based treatments for rare genetic diseases through gene therapy.
NASDAQ: RGNX
Developing innovative inhaled therapies for severe respiratory diseases.
Acquired by Centocor Ortho Biotech
Developing gene therapies for retinal diseases causing blindness.
Builds intelligent, automated picking solutions for warehouse fulfillment.
Developing RNA-based therapeutics for immune modulation and viral defense.
Discovering and developing novel first-in-class small molecule drugs with the potential to address multiple psychiatric indications.
Developing cell and gene therapies for complex diseases.
NASDAQ: SANA
Developing cell therapies for treating type 1 diabetes.
Acquired by Vertex
A leading global provider of image grade LiDAR technology, enabling autonomy for intelligent transportation, robotics and industrial automation.
Developing therapies that target aging at the cellular level.
Pioneering novel immunotherapies for cancer treatment.
Facilitating data-driven life science research and empowering drug R&D processes.
Developing advanced DNA sequencing solutions though genomics technology.
NASDAQ: OMIC
Developing treatments for age-related degenerative diseases.
Developing innovative treatments for genetic diseases through gene therapy.
Developing oral therapies for chronic metabolic and cardiovascular diseases.
NASDAQ: GPCR
Developing next-generation antibody therapies focused on the tumor microenvironment.
NASDAQ:SURF
Developing innovative treatments for women’s health conditions.
Advancing TCR bispecific therapies for cancer and autoimmune disorders.
Transforming global drug discovery with advanced AI and physics-based technologies.
Provides diagnostic equipment designed to offer services and support in the field of obstetrics and gynecology and pathology
Acquired by Hologic
Retrofitting construction and mining equipment for supervised autonomy.
Develops small molecule therapeutics designed to effectively treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
NASDAQ: TPST
Developing a novel therapy to treat presbyopia.
Improving the lives of patients and caregivers impacted by neurological, cardiometabolic, and ophthalmic diseases.
Developing antibiotics for multi-drug-resistant infections.
NASDAQ: TTPH
Developing treatments for pediatric infectious diseases.
Acquired by Sanofi
Developing inhaled therapies for respiratory and lung infections.
Acquired by Insmed Inc.
Developing diagnostic and imaging solutions for healthcare providers.
Developing cancer therapies that activate T-cell responses through immuno-oncology.
NASDAQ: TSBX
Developing innovative treatments for rare and ultra-rare diseases.
NASDAQ: RARE
Developing treatments for cardiovascular diseases though gene-editing.
NASDAQ: VERV
Developing treatments for dermatological conditions like rosacea.
Acquired by Allergan
Developing MRI-guided radiation therapy systems for cancer treatment.
NASDAQ: VRAY
Developing treatments for immuno-inflammatory conditions.
NASDAQ: VYNE
Engineering tumor-activated therapies for targeted cancer treatment.
NASDAQ: XLO
Developing minimally invasive treatments for benign prostatic hyperplasia.
The companies identified do not represent all the companies purchased, sold, or recommended for portfolios advised by F-Prime.